更多栏目
搜索
China Licensing Deals Tracker: Mar 2021
储旻华·2021-05-13
PharmaDJ
In-Licensing Deals Bring New Acid Reflux and Ophthalmic Treatments in to China

China Licensing Deals Tracker: Mar 2021


Writer: Minhua Chu

Editor: Justin Fischer


March 2021 saw 16 licensing deals for innovative drugs in China. Once again, in-licensing continues to account for the majority of the deals with a total of 10 transactions.



Eight of them were were publicly disclosed with a total value of $896.6 million, a figure slightly lower than that of February.  



The largest deal of the month was a contract between Korean firm Daewoong Pharmaceutical and Shanghai Haini Pharmaceutical, a subsidiary of the Yangtze River Pharmaceutical Group (YRPG), to license out fexuprazan to China. The $338 million contract includes an upfront payment of $18 million plus $12 million milestones.


Fexuprazan is a new P-CAB (potassium-competitive acid blocker) drug for the treatment of gastro esophageal reflux. The drug has already been approved by the NMPA to enter phase III clinical trials. According to Korea Biomedical Review, Daewoong plans to proceed with phase I trials on approximately 30 people in the first half of this year and then complete phase III clinical trials by 2022. 


Founded in 1971, YRPG is a private company and has topped the “China Pharmaceutical Industry Top 100” six years in a row since 2014. According to the audit report YRPG submitted to the State Administration for Market Regulation (SAMR), its annual revenue reached RMB25.467 billion ($3.93 billion) in 2018.


This is the second time in six months that YRPG has introduced overseas assets through its subsidiary Shanghai Haini. In December 2020, the company also signed an exclusive licensing agreement with Allecra Therapeutics to acquire the manufacturing, development and commercialization rights to cefepime-enmetazobactam in Greater China.



LianBio and Tarsus also inked a lucrative deal in March. As a result, LianBio has obtained the rights to TP-03 (lotilaner ophthalmic solution, 0.25%), a first-in-class investigational treatment,  from Tarsus. Valued at $100 million, the contract includes a $15 million upfront payment and up to $185 million in development and commercialization milestones as well as tiered low double-digit royalties based on sales. TP-03 is in development for the treatment of eye conditions, including demodex blepharitis and meibomian gland dysfunction (MGD).


文章关键字: China Licensing Deals Tracker Acid Reflux Ophthalmic Yangtze River Pharmaceutical Group (YRPG) Daewoong Pharmaceutical Haini Pharmaceutical fexuprazan P-CAB State Administration for Market Regulation (SAMR)
3324
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明